ZINC CATION

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	Zn
Molecular Weight	65.3956
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	2

SHOW SMILES / InChI

Structure Search

SMILES

[ZnH2+2]

InChI

InChIKey=PTFCDOFLOPIGGS-UHFFFAOYSA-N

InChI=1S/Zn/q+2

HIDE SMILES / InChI

Molecular Formula	Zn
Molecular Weight	65.3956
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459http://www.t3db.ca/toxins/T3D0733http://www.hmdb.ca/metabolites/HMDB01303http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/https://www.google.com/patents/US3130034
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6309044

Diammonium Zinc Disulfate is commonly used in fluid fertilizers. It is effective if properly applied in the soil (band application) and is less costly than chelate forms of zinc.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Streptococcus mutans 40 Target ID: CHEMBL612426 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 \| https://www.ncbi.nlm.nih.gov/pubmed/2913640	Inhibitor 7709
respiratory burst 38 Target ID: GO:0045730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8157083	Activator 1337
transformed cell apoptotic process 106 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Activator 1337
Methotrexate 37 Target ID: CHEMBL2364710 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Hydrolytic Enzyme 37
Target ID: ultraviolet B-induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/25947194	Interacts 316
T cell mediated immunity 39 Target ID: GO:0002456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Activator 1337
Zinc transporter ZIP1 37 Target ID: Q9NY26 Gene ID: 27173.0 Gene Symbol: SLC39A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 994
Zinc transporter ZIP2 37 Target ID: Q9NP94 Gene ID: 29986.0 Gene Symbol: SLC39A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 994

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2501
Unknown 2501
Unknown 2501
Caries 42 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 https://www.ncbi.nlm.nih.gov/pubmed/2913640 https://www.ncbi.nlm.nih.gov/pubmed/6353570	Preventing	Basic research	Unknown Approved Use Unknown
Ulcerative colitis 117 Sources: https://www.drugs.com/international/corticotropin-zinc-hydroxide.html https://www.ncbi.nlm.nih.gov/pubmed/13469787	Primary	Approved 8003	CORTROPHIN-ZINC Approved Use Treatment of ulcerative colitis and other colonic disorders. Launch Date -4.55328006E11
Zinc deficiency 38 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6383773	Primary	Preclinical	Unknown Approved Use Unknown
Acute myeloid leukemia 128 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Primary	Basic research	Unknown Approved Use Unknown
Breast cancer 411 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27305766	Primary	Basic research	Unknown Approved Use Unknown
Renal insufficiency 39 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Secondary	Approved 8003	VORAXAZE Approved Use Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate. Launch Date 1.32675836E12
Diaper dermatitis 37 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021026s000lbl.pdf	Primary	Approved 8003	VUSION Approved Use INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. Launch Date 1.140048E12
Poison Ivy dermatitis 37 Sources: https://www.drugs.com/cdi/zinc-oxide-cream.html	Primary	Approved 8003	ZINC OXIDE Approved Use Unknown
Gastrointestinal disorders 92 Sources: https://www.drugs.com/pro/zinc-sulfate-injection.html	Primary	Approved 8003	ZINC SULFATE Approved Use Unknown Launch Date 5.47171205E11
Mucositis 38 Sources: https://clinicaltrials.gov/ct2/show/NCT01015183	Primary	Phase III 651	ZINC SULFATE Approved Use Unknown Launch Date 5.47171205E11
Dysgeusia 37 Sources: https://clinicaltrials.gov/ct2/show/NCT00036881	Primary	Phase III 651	ZINC SULFATE Approved Use Unknown Launch Date 5.47171205E11
Unknown 2501

PubMed

Title	Date	PubMed
In vitro activity of zinc salts against human rhinoviruses.	1987 Apr	3038000
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1.	1991 Sep 10	1888732
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.	1993 Aug	8404763
New applications for the zinc iodide-osmium tetroxide technique.	1994 Feb	7512543
Iron chelators as therapeutic agents against Pneumocystis carinii.	1994 May	8067783
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.	1995 Nov 13	7488149
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.	1997 Feb	9021177
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide.	1997 May 16	11671728
Thujaplicin-copper chelates inhibit replication of human influenza viruses.	1998 Aug	9806486
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.	1999 Spring	10686872
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.	2004	16145958
Impact of the mother's zinc deficiency on the woman's and newborn's health status.	2005	16240669
Zinc in attention-deficit/hyperactivity disorder.	2005 Aug	16190793
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.	2005 Aug	16042674
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.	2005 Sep 1	16118778
Effects of zinc supplementation in patients with type 1 diabetes.	2005 Summer	16034148
Copper and zinc concentrations in serum of healthy Greek adults.	2006 Apr 15	15955548
Effect of end-stage renal disease and diabetes on zinc and copper status.	2006 Jul	16943612
Elevated cortical zinc in Alzheimer disease.	2006 Jul 11	16832080
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality.	2006 May	16757839
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.	2006 May	16636303
On the mechanism of the conversion of methanol to 2,2,3-trimethylbutane (triptane) over zinc iodide.	2006 Nov 10	17081022
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.	2007 May	17301066
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.	2007 Nov	18055849
Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity.	2010 Dec	21119035
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.	2010 Dec	20729176
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.	2010 Dec 1	20851137
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.	2010 Feb	19755143
Glucarpidase following high-dose methotrexate: update on development.	2010 Jan	19925307
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.	2010 Jul	20194077
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.	2011 Jul	21481475
Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.	2011 Jun	19833686
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?	2011 Mar 1	21220601
Responses of human cells to ZnO nanoparticles: a gene transcription study.	2011 Nov	21769377
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.	2012 Apr	22240982
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.	2012 Feb	21964423
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.	2012 Jun 25	22640810
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.	2013 Dec	23519475
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.	2013 Dec	24060544
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.	2013 Jan	22083529
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.	2013 Jul 31	23726862
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.	2013 Nov 25	24120544
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.	2013 Sep	23352990
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.	2014 Apr	24368203
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.	2014 Jan	23832296
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.	2014 Jul 1	24746987
Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.	2014 May 15	24780487
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.	2014 May 16	24631018
Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand.	2015 Jan 25	25173522
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.	2015 Sep	25940351

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:26:35 UTC 2021` Edited by `admin` on `Fri Jun 25 21:26:35 UTC 2021`
Record UNII	13S1S8SF37
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZINC CATION

Common Name

English

ZINC ION

Common Name

English

ZINC(II)

Systematic Name

English

ZINC ION(2+)

Common Name

English

ZINC(2+)

Systematic Name

English

ZINC, ION (ZN2+)

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175530